Cardio-respiratory depressants- 
Fospropofol may  produce additive cardio-respiratory effects when administred with
other cardio-respiratory depressants eg, sedative hynotics and narcotic analgesics

Monitored anesthesia care
 

Common adverse reactions-

CNS -     headache  1%   parethesia 72%

Miscellaneous-    hypotension 2%    pruritus   14%

Special Precautions-

Respiratory depression- consider additive cardio-respiratory effects of narcotic analgesics
and sedative -hypnotic agents when administered  concomittantly with fospropofol

Hypotension- patients with compromised myocardial function , reduced vascular tone or
who have reduced intravascular volume may be at increased risk for hypotension

Hepatic function impairment- caution should be excercised when useing fospropofol with
hepatic function impairment

Pregnancy- this drug should be used during pregnancy only if clearly needed.

Lactation- fospropofol is not recommended for use in breast feeding mothers

Children- safety and efficacy in children have not been established

Elderly- patients 65 years of age and older should receive lower dosing regimen

Indication-
Monitored anesthesia care

Dosage-
Intial dose should not exceed 16.5ml supplemental dose should not exceed 4ml

1. Paresthesias, including burning, tingling, stinging and or pruritus, usually manifested in
   the peripheral region  are frequently experienced upon injection of the initial dose of
   fosfoprofol.
   Inform patients that these symptoms are typically mild to moderate , last
   a short time and require no treatment

2. The timing of when the patient who have received fospropofol can engage in
     activites requiring complete mental  alertness should be decided by the doctor 

Pregnancy-
This drug should be used during pregnancy only if clearly needed.

Lactation-
 Fospropofol is not recommended for use in breast feeding mothers

Children-
Safety and efficacy in children have not been established

Elderly-
Patients 65 years of age and older should receive lower dosing regimen